ClinicalTrials.gg
RecruitingNCT07525375FAROSUpdated Oct 13, 2026

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

A Phase 2 interventional study of GP MDI and BFF MDI in Asthma, sponsored by AstraZeneca. Recruiting at 44 sites in 7 countries. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 13, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
4 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Planned enrollment
167th of 248
69 · median 175
Started
2026
with 9 others
Phase 2
50 of 359
2 open now
Primary completion
2029-05
later than 23 of 27 live
Registered
354th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 167th largest by planned enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2026, is one of 50 in phase 2, reaches primary completion later than 23 of the 27 other live ones, and was the 354th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.

Read the detailed description

This is a Phase II, multi-center, randomized, double-blind, 3-period, 6-sequence crossover study evaluating two doses of GP Metered-Dose Inhaler (MDI) compared with placebo MDI as add-on therapy to BFF MDI.

The study comprises a 3-week run-in period, followed by three 3-week treatment periods where participants will be randomized to one of six treatment sequences, and a safety follow-up visit 12 to 16 days after the last dose of study intervention.

The treatment periods are as follows:

  • Treatment A: BFF MDI + GP MDI Dose A
  • Treatment B: BFF MDI + GP MDI Dose B
  • Treatment C: BFF MDI + Placebo MDI
03

Conditions studied

  • Asthma

Keywords

  • Oral inhalation
  • Metered dose inhaler
  • Add-on therapy
  • Inhaled corticosteroid
  • Long-acting β2-agonists
  • Long-acting muscarinic antagonist
  • Lung Diseases
04

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Participants who have a documented history of physician-diagnosed asthma
  • Participants who have been using a stable and regular inhaled plus one additional asthma controller medication.
  • Participants must have a Childhood Asthma Control Test score ≥ 19.
  • Participants must have a pre-bronchodilator ≤ 95% of predicted normal value.
  • (BMI) ≤ 95 percentile for age and body weight of ≥ 14 kg or higher.
  • Female participants who experience menarche must have a negative urine pregnancy test.
  • Received no asthma medication other than run-in BFF MDI BID and albuterol/salbutamol as needed.

Main Exclusion Criteria:

  • Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
  • Historical or current evidence of a disease including, but not limited to cardiovascular, hepatic, renal, hematological, neurological, endocrine, gastrointestinal, or pulmonary.
  • Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, vital signs, or .
  • Hospitalization for asthma
  • Narrow-angle glaucoma not adequately treated and/or change in vision, bladder dysfunction, bladder outlet obstruction/urinary retention or any other conditions where anticholinergic treatment is and may be relevant.
  • Use of Long-acting muscarinic antagonist (LAMA), either alone or as part of an inhaled combination therapy.
  • Current use of any systemic beta-blockers.
  • Respiratory infection involving antibiotic treatment.
  • Systemic corticosteroid use for any reason (including asthma exacerbations).
  • Participants with a known to beta 2-agonists, corticosteroids, anticholinergics, or any component of the MDI.
  • Participants who are medically unable to withhold their short-acting bronchodilators and other asthma medications.
  • Any use of marketed (eg, omalizumab, mepolizumab, benralizumab, reslizumab) or biologic.
  • Regular use of a nebulizer or a home nebulizer for receiving asthma medications.
  • Use of any immunomodulators or medication.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Treatment Sequence ABC

    Participants will receive three treatments in sequence: Treatment A, Treatment B followed by Treatment C for 3 weeks each.

    Combination Product: GP MDI · Combination Product: BFF MDI · Combination Product: Placebo MDI

  • Experimental
    Treatment Sequence BCA

    Participants will receive three treatments in sequence: Treatment B, Treatment C followed by Treatment A for 3 weeks each.

    Combination Product: GP MDI · Combination Product: BFF MDI · Combination Product: Placebo MDI

  • Experimental
    Treatment Sequence CAB

    Participants will receive three treatments in sequence: Treatment C, Treatment A followed by Treatment B for 3 weeks each.

    Combination Product: GP MDI · Combination Product: BFF MDI · Combination Product: Placebo MDI

  • Experimental
    Treatment Sequence ACB

    Participants will receive three treatments in sequence: Treatment A, Treatment C followed by Treatment B for 3 weeks each.

    Combination Product: GP MDI · Combination Product: BFF MDI · Combination Product: Placebo MDI

  • Experimental
    Treatment Sequence BAC

    Participants will receive three treatments in sequence: Treatment B, Treatment A followed by Treatment C for 3 weeks each.

    Combination Product: GP MDI · Combination Product: BFF MDI · Combination Product: Placebo MDI

  • Experimental
    Treatment Sequence CBA

    Participants will receive three treatments in sequence: Treatment C, Treatment B followed by Treatment A for 3 weeks each.

    Combination Product: GP MDI · Combination Product: BFF MDI · Combination Product: Placebo MDI

Interventions

  • Combination productGP MDI

    GP MDI will be administered via oral inhalation twice daily (BID).

  • Combination productBFF MDI

    BFF MDI will be administered via oral inhalation BID.

  • Combination productPlacebo MDI

    Placebo MDI will be adminsitered via oral inhalation BID.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Forced Expiratory volume in one second (FEV1) at 1-hour post-dose measured at End of treatment (EoT)

    Evaluate the effect of 2 different GP MDI doses relative to placebo MDI as an add-on treatment to BFF MDI on lung function in 4 to less than 12 years old participants with asthma.

    Time frame: at 3 weeks

Secondary outcomes

  1. Change from baseline in morning pre-dose trough FEV1 at EOT

    Evaluate the effect of 2 different GP MDI doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in 4 to less than 12 years old participants with asthma.

    Time frame: at 3 weeks

Other outcomes

  1. Number of participants with adverse events (AEs) and Adverse events of special interest (AESIs)

    To evaluate the safety profile of GP MDI relative to placebo MDI as add-on treatment to BFF MDI in participants aged 4 to less than 12 years.

    Time frame: Up to Follow-up (2 weeks after last dose)(Approximately 14 weeks)

07

Study locations

20 of 44 sites recruiting
  • Research Site
    Bakersfield, California 93301, United States
    Recruiting
  • Research Site
    Lancaster, California 93534, United States
    Recruiting
  • Research Site
    Long Beach, California 90806, United States
    Recruiting
  • Research Site
    San Diego, California 92123, United States
    Not yet recruiting
  • Research Site
    Miami, Florida 33125, United States
    Recruiting
  • Research Site
    Pembroke Pines, Florida 33026, United States
    Recruiting
  • Research Site
    Saint Cloud, Florida 34769, United States
    Recruiting
  • Research Site
    Owensboro, Kentucky 42301, United States
    Recruiting
  • Research Site
    Lafayette, Louisiana 70508, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    Columbia, Missouri 65203, United States
    Recruiting
  • Research Site
    Cincinnati, Ohio 45229, United States
    Not yet recruiting
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
    Recruiting
  • Research Site
    Lewisville, Texas 75067, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78249, United States
    Recruiting
  • Research Site
    Buenos Aires, C1122, Argentina
    Recruiting
  • Research Site
    CABA, 1426, Argentina
    Recruiting
  • Research Site
    La Plata, B1900AXI, Argentina
    Not yet recruiting
  • Research Site
    Lanús Este, B1824KAJ, Argentina
    Not yet recruiting
  • Research Site
    Lobos, 7240, Argentina
    Not yet recruiting
  • Research Site
    Mar del Plata, B7600, Argentina
    Not yet recruiting
  • Research Site
    Mendoza, 5500, Argentina
    Not yet recruiting
  • Research Site
    Mendoza, M5500, Argentina
    Recruiting
  • Research Site
    Rosario, 2000, Argentina
    Not yet recruiting
  • Research Site
    Rosario, S2000CVD, Argentina
    Recruiting
  • Research Site
    San Juan Bautista, 1888, Argentina
    Not yet recruiting
  • Research Site
    Santa Fe, 3000, Argentina
    Not yet recruiting
  • Research Site
    Brno, 65691, Czechia
    Not yet recruiting
  • Research Site
    Prague, 15006, Czechia
    Not yet recruiting
  • Research Site
    Budapest, 1033, Hungary
    Not yet recruiting
  • Research Site
    Debrecen, 4032, Hungary
    Recruiting
  • Research Site
    Orosháza, 5900, Hungary
    Not yet recruiting
  • Research Site
    Szeged, 6720, Hungary
    Recruiting
  • Research Site
    Székesfehérvár, 8000, Hungary
    Not yet recruiting
  • Research Site
    Szigetvár, 7900, Hungary
    Recruiting
  • Research Site
    Apodaca, 64620, Mexico
    Not yet recruiting
  • Research Site
    Guadalajara, 44130, Mexico
    Not yet recruiting
  • Research Site
    San Juan, 00909, Mexico
    Not yet recruiting
  • Research Site
    Lodz, 90-329, Poland
    Recruiting
  • Research Site
    Tarnów, 33-100, Poland
    Not yet recruiting
  • Research Site
    Belgrade, 11000, Serbia
    Not yet recruiting
  • Research Site
    Belgrade, 11040, Serbia
    Not yet recruiting
  • Research Site
    Belgrade, 11070, Serbia
    Not yet recruiting
  • Research Site
    Novi Sad, 21000, Serbia
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2029, 37 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 37 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 13, 2026
StartActual
Apr 14, 2026
Primary completionEst.
May 23, 2029
CompletionEst.
May 23, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • Research Site · San Antonio, United StatesNot yet recruiting→Recruiting
  • Research Site · Buenos Aires, ArgentinaNot yet recruiting→Recruiting
  • Research Site · CABA, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Mendoza, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Rosario, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Debrecen, HungaryNot yet recruiting→Recruiting
  • Research Site · Szigetvár, HungaryNot yet recruiting→Recruiting
  • Research Site · Lodz, PolandNot yet recruiting→Recruiting
Show site
  • Research Site · Budapest, Hungary
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • Research Site · San Antonio, United StatesNot yet recruiting→Recruiting
    • Research Site · Buenos Aires, ArgentinaNot yet recruiting→Recruiting
    • Research Site · CABA, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Mendoza, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Rosario, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Debrecen, HungaryNot yet recruiting→Recruiting
    • Research Site · Szigetvár, HungaryNot yet recruiting→Recruiting
    • Research Site · Lodz, PolandNot yet recruiting→Recruiting
    Show site
    • Research Site · Budapest, Hungary
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07525375
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 13, 2026
Start date
Apr 14, 2026
Primary completion
May 23, 2029 (estimated)
Completion
May 23, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion